US FDA to tighten COVID-19 vaccine authorization standards ahead of polls | Inquirer News

US FDA to tighten COVID-19 vaccine authorization standards ahead of polls

/ 06:40 AM September 23, 2020

COVID-19, vaccine

FILE PHOTO: Small bottles labeled with a “Vaccine COVID-19” sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/Illustration

The U.S. Food and Drug Administration is expected to soon announce new, more stringent standards for an emergency authorization of a COVID-19 vaccine, lowering the chances that one might be cleared for use before the Nov. 3 election, the Washington Post reported on Tuesday.

The agency is issuing the guidance to boost transparency and public trust as health experts have become increasingly concerned that the Trump administration might be interfering in the approval process, the newspaper said.

Article continues after this advertisement

According to the report, the FDA is expected to ask vaccine manufacturers seeking an emergency authorization to follow trial participants for a median of at least two months after they receive a second vaccine shot. It also said the agency is asking that trials identify a specific number of severe cases of COVID-19 in patients who received a placebo in the trials.

FEATURED STORIES

Few vaccine developers were expected to have definitive trial results before the presidential election. Pfizer Inc had been the exception, although its timetable could slip with the new guidance.

Moderna Inc has said it is unlikely to have data in October. AstraZeneca Plc’s trial in the United States is halted while investigators try to determine whether a serious neurological problem suffered by one participant in the company’s U.K. trial was caused by the vaccine.

Article continues after this advertisement

Moderna and Pfizer began their late-stage trials on July 27, and took about a month to enroll 15,000 people, the halfway point for their initial planned enrollment.

Article continues after this advertisement

The trials are designed for people to receive their second shot either three or four weeks after the first. Two months of follow-up would make it unlikely the companies would have enough data before mid-November.

Article continues after this advertisement

Pfizer said on Tuesday that based on current infection rates it still expects to know whether or not their vaccine works as early as the end of October. Pfizer’s trial protocol calls for an early look at the data after just 32 participants become infected.

“We anticipate providing FDA with safety data, including the median of two months safety data after the second dose, on a rolling basis to help inform FDA’s ultimate determination of authorization or approval,” the drugmaker said in an emailed statement.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: COVID-19 Vaccine, United States

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.